A study describing the cognitive decline over time in adults with myotonic dystrophy type 1 (DM1) was published in the scientific journal Neuromuscular Disorders. The study, titled “Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study” assessed the cognitive ability of the participants over a period of nine years and is the longest study to date with the largest group of participants.
News
Researchers identified a group of cells called fibrocytes that may contribute to inflammation and fibrosis leading to muscle loss in Duchenne muscular dystrophy (DMD). The study, “Identification And Function Of Fibrocytes In Skeletal Muscle Injury Repair And Muscular Dystrophy,” was published in The Journal of Immunology. The muscle…
Detection of the protein dysferlin may help doctors diagnose cases of Miyoshi myopathy (MM), a muscular disorder that primarily affects muscles of the hands and feet, according to a case study published in the journal Experimental And Therapeutic Medicine. In the study, “Atypical Miyoshi Distal Myopathy: A Case…
About 1 in 4 women whose sons have Duchenne or Becker muscular dystrophy were unaware of their carrier status and their own risk of cardiac problems, according to the results of a survey conducted by researchers at the University of Michigan. The study based on the survey, ”Knowledge of carrier status…
The Muscular Dystrophy Association (MDA) and Jiffy Lube service centers have been partners in the annual Muscle Up! campaign since 2012, joining forces to help people with muscular dystrophy (MD) live longer and grow stronger. On its 5th anniversary, the organizations are announcing that more than $5…
Exondys 51 (eteplirsen) was approved by the U.S. FDA for the treatment of Duchenne muscular dystrophy (DMD) on Sept. 19, but the drug helps only 13 percent of those battling the disease. Now, CureDuchenne is redoubling its efforts to find treatments for the 87 percent of DMD…
At Catabasis Pharmaceuticals’ first Investor Day earlier this month, the company provided an in-depth review of its strategy and development pipeline of product candidates for treating rare diseases, including the Duchenne muscular dystrophy drug edasalonexent (CAT-1004). Guest speakers included Craig McDonald, MD, director of the NeuroNEXT Program at…
Researchers recently created a 3D image of the structure and composition of the skeletal muscle, including muscle affected by fibrosis, using multiple imaging techniques coupled with quantitative stereology. The study from a research team at UC San Diego and the Rehabilitation Institute of Chicago, titled “High-resolution three-dimensional reconstruction of fibrotic skeletal muscle…
News
Society Produces Guide on Gene Editing, a Potentially Beneficial Technique for MD, Other Diseases
The American Society of Gene and Cell Therapy (ASGCT), the primary professional body for gene and cell therapy, recently produced a guide on therapeutic gene editing to inform policy-makers, patient advocates, and the general public about the technique.
A retrospective analysis of the brain structure by MRI shows alterations in white matter in patients with myotonic dystrophy type 1 (DM1) disease. These findings suggest the brain is involved in DM1 in addition to the muscular and systemic symptoms already affecting these patients. The study, “MRI findings and cognitive…
Recent Posts
- MDA 2026: More dietary protein linked to better lower limb function in MD
- ‘The Wonder Years’ were the ‘worry years’ before my MD diagnosis
- What’s on my wish list for my family’s Duchenne dream home
- DMD gene therapy can repair muscle fibers but fails to halt tissue scarring
- How AI can support my daily life with Duchenne muscular dystrophy